Abstract
Recent findings indicate an important role for RNA-mediated gene expression in motor neuron diseases, including ALS (amyotrophic lateral sclerosis) and SMA (spinal muscular atrophy). ALS, also known as Lou Gehrig’s disease, is an adult-onset progressive neurodegenerative disorder, whereby SMA or “children’s Lou Gehrig’s disease” is considered a pediatric neurodevelopmental disorder. Despite the difference in genetic causes, both ALS and SMA share common phenotypes; dysfunction/loss of motor neurons that eventually leads to muscle weakness and atrophy. With advanced techniques in molecular genetics and cell biology, current data suggest that these two distinct motor neuron diseases share more than phenotypes; ALS and SMA have similar cellular pathological mechanisms including mitochondrial dysfunction, oxidative stress and dysregulation in RNA-mediated gene expression. Here, we will discuss the current findings on these two diseases with specific focus on RNA-mediated gene regulation including miRNA expression, pre-mRNA processing and RNA binding proteins.
Keywords: Amyotrophic lateral sclerosis, microRNA, motor neuron disease, mRNA translation, RNA binding proteins, SMN, Spinal muscular atrophy, TDP-43/FUS.
CNS & Neurological Disorders - Drug Targets
Title:Dysregulation of RNA Mediated Gene Expression in Motor Neuron Diseases
Volume: 15 Issue: 8
Author(s): Inês do Carmo G. Gonçalves, Wiebke A. Rehorst and Min Jeong Kye
Affiliation:
Keywords: Amyotrophic lateral sclerosis, microRNA, motor neuron disease, mRNA translation, RNA binding proteins, SMN, Spinal muscular atrophy, TDP-43/FUS.
Abstract: Recent findings indicate an important role for RNA-mediated gene expression in motor neuron diseases, including ALS (amyotrophic lateral sclerosis) and SMA (spinal muscular atrophy). ALS, also known as Lou Gehrig’s disease, is an adult-onset progressive neurodegenerative disorder, whereby SMA or “children’s Lou Gehrig’s disease” is considered a pediatric neurodevelopmental disorder. Despite the difference in genetic causes, both ALS and SMA share common phenotypes; dysfunction/loss of motor neurons that eventually leads to muscle weakness and atrophy. With advanced techniques in molecular genetics and cell biology, current data suggest that these two distinct motor neuron diseases share more than phenotypes; ALS and SMA have similar cellular pathological mechanisms including mitochondrial dysfunction, oxidative stress and dysregulation in RNA-mediated gene expression. Here, we will discuss the current findings on these two diseases with specific focus on RNA-mediated gene regulation including miRNA expression, pre-mRNA processing and RNA binding proteins.
Export Options
About this article
Cite this article as:
Gonçalves do Carmo G. Inês, Rehorst A. Wiebke and Kye Jeong Min, Dysregulation of RNA Mediated Gene Expression in Motor Neuron Diseases, CNS & Neurological Disorders - Drug Targets 2016; 15 (8) . https://dx.doi.org/10.2174/1871527315666160815164808
DOI https://dx.doi.org/10.2174/1871527315666160815164808 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Denosumab: The Era of Targeted Therapies in Bone Metastatic Diseases
Current Cancer Drug Targets Curcumin: Powerful Immunomodulator from Turmeric
Current Immunology Reviews (Discontinued) Patent Annotations
Recent Patents on Anti-Cancer Drug Discovery Review of the Contribution of Radiolabelled Tracers for Tumour Cell Status Imaging
Current Medical Imaging Pyrroles and Fused Pyrroles: Synthesis and Therapeutic Activities
Mini-Reviews in Organic Chemistry Role of microRNAs in Osteoblasts Differentiation and Bone Disorders
Current Medicinal Chemistry Editorial (Thematic Issue: Research and Regulation: Challenges of Nanoproducts)
Recent Patents on Nanomedicine Nucleic Acid-based Technologies in Therapy of Malignant Gliomas
Current Pharmaceutical Biotechnology Monocytes Mediate HIV Neuropathogenesis: Mechanisms that Contribute to HIV Associated Neurocognitive Disorders
Current HIV Research Natural Polyphenols and their Synthetic Analogs as Emerging Anticancer Agents
Current Drug Targets Pathobiology and Prevention of Cancer Chemotherapy-Induced Bone Growth Arrest, Bone Loss, and Osteonecrosis
Current Molecular Medicine Radiolabeled Nanoparticles for Cancer Diagnosis and Therapy
Anti-Cancer Agents in Medicinal Chemistry Active-Targeted Nanotherapy Strategies for Prostate Cancer
Current Cancer Drug Targets Activin Receptor-Like Kinase 1: a Novel Anti-angiogenesis Target from TGF-β Family
Mini-Reviews in Medicinal Chemistry Phosphatidylinositol 3-kinase Signaling as a Therapeutic Target for Cervical Cancer
Current Cancer Drug Targets HtrA Serine Proteases as Potential Therapeutic Targets in Cancer
Current Cancer Drug Targets Recent Clinical Trials of mTOR-Targeted Cancer Therapies
Reviews on Recent Clinical Trials The MYC Oncogene as a Cancer Drug Target
Current Cancer Drug Targets Acridine Orange is an Effective Anti-Cancer Drug that Affects Mitochondrial Function in Osteosarcoma Cells
Current Pharmaceutical Design Glioma Stem Cell Maintenance: The Role of the Microenvironment
Current Pharmaceutical Design